Aspirin Dose Optimized in Non-Cardioembolic Ischemic Stroke "ADONIS"


Phase N/A Results

Trial Description

To determine the optimal dose of acetylsalicylic acid (ASA) that would minimize both the recurrence of noncardioembolic ischemic stroke and the risk of drug-related adverse events.


Trial Design

Double-blind, randomized, multicenter study.

Patient Involvement

Eligible patients will be randomized to receive 40, 80, 160, 325, 650, 975, or 1300 mg/day of ASA. They will be followed-up for two years.


Type Measure Time Frame Safety Issue
Primary Recurrent stroke, MI, vascular death, serious adverse events at 2 years.


United Laboratory & Philippine Council for Health Research and Development